BioScrip (NASDAQ:BIOS) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a report issued on Saturday.
Several other brokerages have also recently weighed in on BIOS. Zacks Investment Research raised shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. SunTrust Banks set a $4.00 price target on shares of BioScrip and gave the stock a “buy” rating in a research report on Thursday, December 21st. Finally, ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $3.63.
Shares of BioScrip (NASDAQ:BIOS) opened at $2.97 on Friday. BioScrip has a 52-week low of $1.35 and a 52-week high of $3.39. The firm has a market cap of $378.72, a P/E ratio of -4.79 and a beta of 0.19. The company has a debt-to-equity ratio of -6.11, a current ratio of 1.91 and a quick ratio of 1.60.
A number of large investors have recently bought and sold shares of BIOS. Royce & Associates LP lifted its position in BioScrip by 942.6% during the fourth quarter. Royce & Associates LP now owns 1,824,500 shares of the company’s stock valued at $5,309,000 after acquiring an additional 1,649,500 shares during the last quarter. BlackRock Inc. lifted its position in BioScrip by 10.2% during the fourth quarter. BlackRock Inc. now owns 6,584,105 shares of the company’s stock valued at $19,161,000 after acquiring an additional 611,302 shares during the last quarter. Fuller & Thaler Asset Management Inc. purchased a new stake in BioScrip during the third quarter valued at approximately $1,642,000. Gilder Gagnon Howe & Co. LLC lifted its position in BioScrip by 3.6% during the third quarter. Gilder Gagnon Howe & Co. LLC now owns 15,764,337 shares of the company’s stock valued at $43,352,000 after acquiring an additional 553,201 shares during the last quarter. Finally, FMR LLC lifted its position in BioScrip by 10.8% during the second quarter. FMR LLC now owns 5,323,231 shares of the company’s stock valued at $14,453,000 after acquiring an additional 520,231 shares during the last quarter. 84.53% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.com-unik.info/2018/02/10/bioscrip-bios-raised-to-buy-at-bidaskclub.html.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.